What is the current Price Target for the Apogee Therapeutics stock?

The average Apogee Therapeutics target price is $96.14. This is 154.14% higher than the current stock price. The highest price target is 206.63%, the lowest is 132.62%. 7 Analysts have issued a price target Apogee Therapeutics 2026 .

How high will the Apogee Therapeutics stock rise?

No reliable answer can be given as to how high the Apogee Therapeutics stock will rise. The performance of stocks, including the Apogee Therapeutics stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Apogee Therapeutics stock today?

The performance of Apogee Therapeutics stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Apogee Therapeutics stock fall?

The decline in Apogee Therapeutics stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Apogee Therapeutics Forecast, price target & analysts

$35.35

6.56% today

NYSE, Apr 03, 06:50 pm CET

ISIN

US03770N1019

Symbol

APGE

Reports

Quarter | Annual

Index

S&P SmallCap 600

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Apogee Therapeutics Target price 2025 - Analyst rating & recommendation

Apogee Therapeutics Classifications & Recommendation:

Buy

100%

Apogee Therapeutics Price Target

Target Price	$96.14
Price	$37.83
Potential	154.14% register free of charge
Number of Estimates	7

	7 Analysts have issued a price target Apogee Therapeutics 2026 . The average Apogee Therapeutics target price is $96.14. This is 154.14% register free of charge higher than the current stock price. The highest price target is $116.00 206.63% register free of charge , the lowest is $88.00 132.62% register free of charge .
	A rating was issued by 8 analysts: 8 Analysts recommend Apogee Therapeutics to buy, 0 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Apogee Therapeutics stock has an average upside potential 2026 of 154.14% register free of charge . Most analysts recommend the Apogee Therapeutics stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-3.30	-4.97
	98.80%	50.61%
P/E		negative

4 Analysts have issued a Apogee Therapeutics forecast for earnings per share. The average Apogee Therapeutics EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-3.30	98.80%
2025	$-4.97 50.61% Unlock
2026	$-5.46 9.86% Unlock
2027	$-5.31 2.75% Unlock
2028	$-6.58 23.92% Unlock
2029	$-3.25 50.61% Unlock

Current
2025	-7.62 34.93% Unlock
2026	-6.93 9.06% Unlock
2027	-7.12 2.74% Unlock
2028	-5.75 19.24% Unlock
2029	-11.64 102.43% Unlock

Apogee Therapeutics...

Current Apogee Therapeutics Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
Citigroup	Locked ➜ Locked	Locked	Mar 13 2025
Guggenheim	Locked ➜ Locked	Locked	Feb 10 2025
Guggenheim	Locked ➜ Locked	Locked	Dec 12 2024
Guggenheim	Locked ➜ Locked	Locked	Dec 03 2024
Wedbush	Locked ➜ Locked	Locked	Dec 02 2024
Guggenheim	Locked ➜ Locked	Locked	Nov 27 2024
Canaccord Genuity	Locked ➜ Locked	Locked	Nov 25 2024

Analyst Rating	Date
Locked Citigroup: Locked ➜ Locked	Mar 13 2025
Locked Guggenheim: Locked ➜ Locked	Feb 10 2025
Locked Guggenheim: Locked ➜ Locked	Dec 12 2024
Locked Guggenheim: Locked ➜ Locked	Dec 03 2024
Locked Wedbush: Locked ➜ Locked	Dec 02 2024
Locked Guggenheim: Locked ➜ Locked	Nov 27 2024
Locked Canaccord Genuity: Locked ➜ Locked	Nov 25 2024

Discover more stocks with a high price target

Novo Nordisk 75.12%

Coinbase Global, Inc. 71.30%

BioNTech SE - ADR 48.29%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now